Signal Genetics Prices IPO at $10 per Share, Expects $8.5M in Gross Proceeds | GenomeWeb

NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics has priced its initial public offering at $10 per share with gross proceeds expected at $8.5 million.

The company is offering 850,000 shares of its common shares in its IPO and has granted the underwriters a 45-day option to purchase up to 127,500 additional shares to cover any overallotments. Aegis Capital is the sole book-running manager on the offering.

Signal's shares began trading today on the Nasdaq Capital Market under ticker symbol "SGNL."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.